1.Expression of S100 Protein and GFAP and Their Correlation with Perineural Invasion in Adenoid Cystic Carcinoma
Journal of Medical Research 2006;0(05):-
0.05) and that of GFAP were found(P
2.Changes of HMGB1 and GPX3 in thyroid cancer and their relation with pathologic characteristics
Zhenhua ZHANG ; Yunzhen KAN ; Qiuyu LIU
Chongqing Medicine 2017;46(17):2347-2349,2352
Objective To investigate the changes of high mobility group box 1 (HMGB1),glutathione peroxidase(GPX3) in thyroid carcinoma and thier relationship with pathological characteristics.Methods The levels of HMGB1 and GPX3 were detected by using ELISA in 153 cases of thyroid cancer,120 cases of benign thyroid nodules and 120 healthy controls.The changes of HMGB1 and GPX3 in the patients with thyroid cancer were analyzed.Their application value in thyroid cancer was analyzed by using the receiver operating characteristic(ROC) curve.Results The plasma HMGB1 level and the HMGB1 positive expression rate in the thyroid cancer group were higher than those in the benign thyroid nodules group and control group(P<0.05),while the plasma GPX3 level and GPX3 positive expression rate in the thyroid cancer group were lower than those in the benign thyroid nodules group and control group(P<0.05).There were no significant differences in the levels of plasma HMGB1,GPX3 and the positive rates of HMGB1 and GPX3 between the thyroid benign nodule group and the healthy control group (P > 0.05).The plasma H MGB1 expression in thyroid cancer was closely related with the infiltration degree,clinical stage and lymph node metastasis(P< 0.05),and the GPX3 expression was related with the tumor stage and lymph node metastasis(P<0.05).The ROC curve showed that the sensitivity and specificity of HMGB1 and GPX3 for diagnosing thyroid cancer were 76.3% and 85.5%,70.8% and 82.2% respectively.Conclusion Plasma HMGB1 and GPX3 expression levels are closely associated with the occurrence and progression of thyroid cancer.
3.The feasibility research of dexmedetomidine sedation during cerebral angiography
Lixin WANG ; Yunzhen WANG ; Qing KAN ; Ruquan HAN
Chinese Journal of Postgraduates of Medicine 2013;36(36):14-17
Objective To explore the feasibility and safety of dexmedetomidine sedation in interventional neuroradiology operations.Methods Eighty-five cases ASA grade Ⅱ-Ⅲ grade patients undergoing cerebral angiography according to age divided into two groups:old group(more than 60 years old,35 cases) and young group (18-59 years old,50 cases).The loading dose of dexmedetomidine were dexmedetomidine 0.5 μ g/kg in old group and 1.0 μ g/kg in young group,respectively.The loading dose was administered for 10 min followed by continuous infusion dexmedetomidine 0.5 μ g/ (kg· h).Blood pressure,heart rate (HR),peripheral oxygen saturation (SpO2) and respiratory rate (RR),Ramsay score and bispectral index(BIS) were monitored and recorded during the study.Results The BIS,Ramsay score after administration 10,15,30,45 min in two groups was significantly longer than that before administration [old group:84 ±22,83 ±22,85 ± 15,75 ±23 vs.94 ±5; (2.0 ±0.4),(2.3 ±0.6),(2.8 ±0.7),(3.0 ±0.7)scores vs.(1.7 ± 0.5) scores; young group:91 ± 8,89 ± 11,86 ± 12,81 ± 13 vs.96 ± 2; (1.9 ± 0.6),(2.3 ±0.7),(2.7 ± 0.9),(3.0 ± 0.9) scores vs.(1.6 ± 0.5) scores,P < 0.05].The systolic blood pressure,diastolic blood pressure,mean arterial pressure (MAP) after administration 10,15,30,45 min in two groups was significantly longer than that before administration [old group:(152 ± 23),(144 ± 23),(140 ± 21),(135 ±21) mm Hg(1 mm Hg =0.133 kPa) vs.(165 ± 25) mm Hg; (87 ± 11),(83 ± 11),(78 ± 8),(75 ± 8) mm Hg vs.(89± 13)mm Hg;(106±14),(100±13),(99±12),(95±12)mm Hg vs.(113±16)mm Hg;young group:(131 ± 24),(127 ± 23),(124 ± 25),(124 ± 26) mm Hg vs.(142 ± 23) mm Hg; (81 ± 13),(79±13),(77±13),(76±13)mmHgvs.(86± 14) mmHg;(97±16),(94±16),(91±19),(92±20) mm Hg vs.(104 ± 19) mm Hg,P <0.05],but the decreases in blood pressure were <20% from baseline.The HR,RR and SpO2 was no significant difference (P > 0.05).Conclusions Continuous infusion of dexmedetomidine sedation during cerebral angiography has little effect on hemodynamics,no significant respiratory depression,is safe and effective.
4. Study on the effects of target-silencing CXCR3 expression on malignant proliferation of hepatocellular carcinoma
Ying REN ; Yunzhen KAN ; Lingfei KONG
Chinese Journal of Hepatology 2018;26(7):508-512
Objective:
To explicit, the expression of chemokine receptor 3 in HCC tissues and its relationship with overall survival of patients, and to explore the effect of targeted silencing CXCR3 gene on proliferation of hepatocellular carcinoma cells and its mechanism of action.
Methods:
The expression of CXCR3 in 60 cases of hepatocellular carcinoma and its adjacent tissues were detected by immunohistochemistry. The clinicopathological correlations between the expression levels of CXCR3 in hepatoma tissues of liver cancer patients were analyzed and univariate Kaplan-Meier survival analysis was performed in combination with follow-up data. Huh7 hepatoma cells were infected with lentivirus LV-CXCR3-shRNA. The effects of CXCR3 deletion on proliferation of hepatoma cells were determined by CCK-8 assay and tumor-bearing nude mice experiment.
Results:
CXCR3 was highly expressed in HCC tissues, and the overall survival rate (OS) of patients with high CXCR3 expression was significantly lower than that of patients with low expression. After the CXCR3 gene was successfully silenced in Huh7 hepatocellular carcinoma cells, the proliferation ability of Huh7 cells was significantly inhibited in vitro, and the tumor growth rate of nude mice was slowed down, and the activity of JAK-STAT pathway in Huh7 cells was decreased, and the levels of c-MYC and Bcl-xl protein were decreased. In addition, deletion of CXCR3 can effectively inhibit IL-6-mediated JAK-STAT pathway activation.
Conclusion
CXCR3 high expression indicated that the survival rate was poor, and the target silencing of CXCR3 gene could inhibit the proliferation of hepatocellular carcinoma cells and maybe related to inhibition of JAK-STAT pathway activity. CXCR3 may be a potential target for the treatment of hepatocellular carcinoma.